Background
==========

The escalating burden of multidrug resistant (MDR) gram negative bacteria of the family Enterobacteriaceae is currently one of the most challenging situations both in developed and developing countries \[[@B1]-[@B4]\]. The exposure of these bacteria notably, *Escherichia coli* and *Klebsiella pneumoniae* to antibiotics especially in the hospital environment has induced dynamic and continuous mutation leading to production extended spectrum beta lactamase (ESBL) which confer resistance to first, second, third and fourth generation cephalosporins as well as aztreonam \[[@B5]-[@B7]\]. These ESBL strains in turn have spread not only in the hospital environment but also to the community settings with significant regional variations \[[@B4],[@B6],[@B8],[@B9]\].

Although shown in few studies, gastrointestinal carriage of ESBL strains can be a predictor of subsequent infection \[[@B10]-[@B12]\]. The prevalence of ESBL carriage has been shown to range from 3.2% to 67.9% \[[@B12]-[@B16]\]. Furthermore, pregnant women colonized by ESBL in the gastrointestinal tract have a potential to subsequently transmit these strains to their neonates (during and after delivery), to other hospitalized patients and to health workers \[[@B17],[@B18]\].

Few studies have addressed the magnitude of ESBL associated infections with undue complications and deaths in Tanzania \[[@B3],[@B9],[@B19]-[@B21]\] however information showing the ESBL carriage among post-delivery women and their neonates remain to be explored. Thus, this study aimed at evaluating the existence, magnitude and transmission of ESBL strains from post-delivery women to their neonates during or after delivery so as to specifically guide infection prevention and control at Bugando Medical Center (BMC) where ESBL associated infections have been shown to be an independent predictor of deaths among neonates \[[@B3]\].

Methods
=======

Study design and sampling procedures
------------------------------------

This was a cross sectional hospital based study conducted from May to July 2013 in the obstetrics wards, neonatal ICU and neonatal wards at BMC. Post-delivery women who delivered at BMC within 24 hours and who consented to participate in the study were serially recruited and their respective neonates. The sample size of 113 post-delivery women was estimated using Kish Leslie (1965) formula and using a previous prevalence of 8% \[[@B14]\].

Data and clinical sample collection
-----------------------------------

Every post-delivery woman was informed about details regarding the aims of the study. A standardized data collection tool and patients' files were used to collect demographic and clinical data among consented women and their respective neonates.

Then, after a thorough explanation, using sterile cotton swab in Amies transport medium (Biolab, HUNGARY) rectal swabs were collected from women within 24 hours after delivery. To assess acquisition of ESBL strains in neonates, the rectal swabs were collected on day 1, day 3 and day 7 post-delivery. Rectal swab specimens were delivered to the Laboratory within two hours after collection.

Laboratory procedures
---------------------

The rectal swab samples were plated onto MacConkey agar (OXOID, Basingstoke, UK) supplemented with cefotaxime 2 mg/L for preliminary screening of ESBL bacterial isolates and then plates were incubated at 35-37°C for 18--24 hours. All gram negative bacteria were identified using phenotypic characteristics such as lactose fermentation reaction on Mac Conkey agar, Urease, Citrate, Sulphur indole motility (SIM) and Triple sugar iron (TSI) tests as previously described \[[@B22]\].

Susceptibility testing was done using disc diffusion method based on the Clinical Laboratory Standard Institute (CLSI) guideline \[[@B23]\]. The antibiotic discs tested were ampicillin (10 μg), amoxicillin/clavulanate (20/10 μg), ciprofloxacin (5 μg), tetracycline (30 μg), gentamicin (10 μg), sulfamethoxazole/trimethoprim (1.25/23.75 μg), ceftriaxone (30 μg), ceftazidime (30 μg) and imipenem (10 μg) (OXOID, Basingstoke, UK). The phenotypic confirmation of ESBL isolates was done using disc approximation method i.e. ceftazidime (30 μg) and cefotaxime (30 μg) discs were placed equidistant from the amoxicillin/clavunate (20/10 μg) disc, followed by overnight incubation at 37°C for 18--24 hrs. Enhanced zone of inhibition towards amoxicillin/clavulanate disc was considered as positive result for ESBL production whereas interpretation of susceptibility patterns on other antimicrobial disks was done using guidelines laid down in the CLSI, which provides break points corresponding to zone of inhibition diameter \[[@B9],[@B23]\].

Quality control
---------------

Standard laboratory procedures were strictly adhered to so as to avoid contamination. *Escherichia coli* ATCC 25922 and *Escherichia coli* ATCC 35218 were used as negative and positive ESBL controls respectively.

Data management and analysis
----------------------------

The demographic, clinical and laboratory data were entered into Microsoft excel and then exported to the STATA version 11.0 software for analysis according to the objectives of the study. Results were presented into percentages/proportions for categorical variables whereas continuous variables were described as mean (±standard deviation). The difference in distribution of predictor variable was considered significant if p-value was less than 0.05.

Study clearance and ethical consideration
-----------------------------------------

The study was approved by CUHAS/BMC Ethical Review Board, and written informed consent was obtained from every post-delivery woman (who also provided consent for her neonate) before collection of demographic, clinical data and rectal swab specimens.

Results
=======

A total of 113 post-delivery women and 126 neonates with mean age of 26.5 ± 5.5 years and median gestation age \[IQR\] of 39 \[35--40\] weeks respectively were recruited.

The prevalence of ESBL carriage among post-delivery women and neonates were 15% (17/113) and 25.4% (32/126) respectively. The cumulative number of ESBL bacterial isolates among post-delivery women and neonates were found to be 20 and 35 respectively throughout the study (three post-delivery women and neonates had dual ESBL carriage). The most predominant ESBL isolates among post-delivery women were *Escherichia coli* (30%, 6/20) followed by *Enterobacter spp* (20%, 4/20) whereas the predominant species in neonates were *Klebsiella pneumoniae* (77.1%, 27/35) followed by *Escherichia coli* (14.3%, 5/35) (Figure [1](#F1){ref-type="fig"}).
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The acquisition of ESBL isolates among neonates on day 1, day 3 and day 7 were 60.0% (21/35), 25.7% (9/35) and 14.3% (5/35) respectively. Furthermore, there was no phenotypic similarity between ESBL strains from post-delivery women and their respective neonates.

There was no statistical significant association between ESBL-carriage among post-delivery women and variables such as age, mode of delivery, history of antibiotic use in the past or current admission, the presence of i/v line, urinary catheter insitu as well as HIV seropositivity. Neonates given antibiotics were more likely to carry ESBL than those not given \[100% (32/32) versus 86% (81/94), p = 0.018\]. The mortality rates among neonates carrying ESBL was relatively higher as opposed to non-carriers though the difference was not statistically significant (12.5%, 5/32 versus 9.6%, 9/94 respectively; p-value = 0.638) (Tables [1](#T1){ref-type="table"} & [2](#T2){ref-type="table"}).

###### 

Association between ESBL carriage among post-delivery women with variables

  **Variable**                                            **Non ESBL carrier, n (%)**   **ESBL carrier, n (%)**   **p-value**  
  ------------------------------------------------------ ----------------------------- ------------------------- ------------- -------
  **Mean age ± SD**^**ǂ**^                                     27.1 ± 5.5 years            23.4 ± 3.6 years          0.084     
  **Mode of delivery**                                               C/S\*                     36 (37.5)           8 (47.1)     0.456
  SVD\*\*                                                          60 (62.5)                   9 (52.9)                        
  **Admission in the past 30 days**                                   No                       96 (100)            17 (100)      \-
  Yes                                                               0 (0.0)                     0 (0.0)                        
  **Admission in the past 3 months**                                  No                       83 (86.5)           13 (76.5)    0.288
  Yes                                                              13 (13.5)                   4 (23.5)                        
  **Previous use of antibiotics in the past 30 days**                 No                       67 (69.8)           9 (52.9)     0.172
  Yes                                                              49 (30.2)                   8 (47.1)                        
  **Previous use of antibiotics in the past 3 months**                No                       54 (56.3)           7 (41.2)     0.250
  Yes                                                              42 (43.7)                   10 (58.8)                       
  **Antibiotics use in the current admission**                        No                       57 (59.4)           9 (52.9)     0.620
  Yes                                                              39 (40.6)                   8 (47.1)                        
  **Presence of catheter**                                            No                       59 (61.5)           10 (58.8)    0.837
  Yes                                                              37 (38.5)                   7 (41.2)                        
  **Presence of i/v line**                                            No                       54 (56.3)           10 (58.8)    0.844
  Yes                                                              42 (43.7)                   7 (41.2)                        
  **HIV serostatus**                                               Negative                    84 (87.5)           16 (94.1)    0.431
                                                                   Positive                    12 (12.5)            1 (5.9)        

^ǂ^Standard deviation; \*Caesarean section; \*\*Spontaneous vaginal delivery.

###### 

Association between ESBL carriage among neonates with variables

  **Variable**                      **Non ESBL carrier, n**    **ESBL carrier, n**   **p-value**  
  --------------------------------- ------------------------- --------------------- ------------- -------
  **Median gestational (IQR)**^ǂ^   39 (35--40)                    39 (35--40)          0.710     
  **Median birth weight (kg)**      2.6 (1.9-3)                   2.9 (1.7-3.4)         0.365     
  **Sex**                           Female                         44 (46.8%)        17 (53.1%)    0.537
  Male                              50 (53.2%)                     15 (46.9%)                     
  **Mode of Delivery**              C/S\*                          35 (37.2%)        12 (37.5%)    0.979
  SVD\*\*                           59 (62.8%)                     20 (62.5%)                     
  **Ward**                          NICU^×^                        19 (20.2%)         8 (25.0%)    0.569
  C2NU^××^                          75 (79.8%)                     24 (75.0%)                     
  **Antibiotic Use**                No                             13 (13.8%)         0 (0.0%)     0.018
  Yes                               81 (86.2%)                     32 (100.0%)                    
  **Outcome**                       Discharged                     85 (90.4%)        28 (87.5%)    0.638
                                    Died                            9 (9.6%)          4 (12.5%)       

^ǂ^Interquantile range; \*Caesarian section; \*\*Spontaneous vagina delivery; ^×^Neonatal intensive care unit; ^××^Ward C2 neonatal unit.

The ESBL bacterial isolates in this study showed borderline resistance to ciprofloxacin among post-delivery women (55.0%, 11/20) and neonates (34.3%, 13/35). All ESBL strains were sensitive to imipenem (Table [3](#T3){ref-type="table"}).

###### 

Antimicrobial resistance patterns among ESBL isolates from post-delivery women and neonates

  **Antimicrobial agents**    **Post-delivery women, n (%)**   **Neonates, n (%)**
  -------------------------- -------------------------------- ---------------------
  Co-trimoxazole                        20 (100.0)                  25 (71.4)
  Tetracycline                          14 (70.0)                   17 (48.6)
  Gentamicin                            15 (75.0)                   32 (91.4)
  Ciprofloxacin                         11 (55.0)                   12 (34.3)
  Imipenem                               0 (0.0)                     0 (0.0)

Discussion
==========

The prevalence of ESBL carriage among women shown in this study (15%) is relatively close to 10% to 12.7% found in some Asian and African countries \[[@B13],[@B15],[@B16]\] but lower than 3% and 3.2% in Sweden and USA respectively \[[@B11],[@B24]\]. The lower rates in ESBL carriage in developed countries as opposed to developing countries may be attributable to different policies in antimicrobial use and infection control in the respective settings. The present study and a similar one in Madagascar found the rates of ESBL carriage in children to be 15% and 22.1% respectively, with acquisition increasing progressively in the course of hospitalization \[[@B25]\]. This emphasizes the need to protect this vulnerable population of children against the MDR strains in the hospital settings. The predominance of *Escherichia coli* and *Klebsiella pneumonia* producing ESBL strains in this study is also similar to findings in some other studies across the world showing their preponderance in gastrointestinal tract colonization and their evolutionary potential into MDR strains \[[@B12],[@B15],[@B25],[@B26]\].

It is well known that gastrointestinal carriage of ESBL strains among pregnant women can be a potential source of transmitting these resistant strains to their newborns \[[@B17],[@B18]\] but contrary to this, there was no phenotypic similarity between ESBL strains from women and their respective neonates. This suggests that effective control of transmission of ESBL strains at BMC should go beyond mothers and that other possible sources should be further scrutinized so as to curb the growing burden of antimicrobial resistance in Tanzania \[[@B3],[@B20]\] and other countries with similar problem \[[@B4],[@B7]\].

As shown in some other studies \[[@B25]-[@B29]\], previous use of antibiotics among neonates has also been shown to be associated with ESBL carriage in the present study. The possible reason of high neonatal ESBL carriage in our setting may be due to antimicrobial selective pressure conferred by the empirical use of ampiclox and cefotaxime. Therefore, as shown from other settings \[[@B11]\], neonatal screening for ESBL strains and adherence to the rational antimicrobial use policy should be an enduring exercise at BMC. Other predictive factors such as older age, prolonged hospitalization, vaginal delivery, low birth weight and prematurity though shown in other studies \[[@B14],[@B25],[@B26],[@B30]\] were not found to be statistically associated with ESBL carriage in the present study.

The MDR nature of the ESBL isolates in the present study is worrisome as these post-delivery women and their neonates may be the potential sources of these strains in the hospital environment, and should of necessity be among the target groups in infection prevention and control activities at BMC. The present study has shown excellent activity of carbapenems and borderline activity of ciprofloxacin against ESBL strains, the findings which are similar to other studies \[[@B8],[@B25]\].

Conclusion
==========

The carriage rates of ESBL strains among neonates and their mothers at BMC are high. Our findings suggest that neonates acquire these strains from sources other than post-delivery women and more than half acquire them on the first day of life. These two groups should be among the target groups for ESBL screening at BMC so as to prevent ESBL spread in the hospital environment. In the light of these findings, more studies are recommended to further explore the sources of the ESBL strains among neonates.
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